| Company Name: |
ApexBio Technology
|
| Tel: |
+ 1-832-696-8203 |
| Email: |
sales@apexbt.com |
| Products Intro: |
Cas:1234480-84-2
ProductName:LRRK2-IN-1
Brand:apexbt | Product Number:A3558
|
| Company Name: |
Axon Medchem LLC
|
| Tel: |
703 - 9861 |
| Email: |
info@axonmedchem.com |
| Products Intro: |
Cas:1234480-84-2
ProductName:LRRK2-IN-1
Brand:Axon Medchem | Product Number:Axon2493 | Purity:99%
|
| Company Name: |
Abcam Limited
|
| Tel: |
021-2070050 400921018 |
| Email: |
us.orders@abcam.com |
| Products Intro: |
Cas:1234480-84-2
ProductName:LRRK2-IN-1, LRRK2 inhibitor
|
- LRRK2-IN-1
-
- $60.00
-
2026-09-10
- CAS:1234480-84-2
- Purity: 98.82%
- Supply Ability: 10g
- LRRK2-IN-1
-
- $1.00
-
2019-12-24
- CAS:1234480-84-2
- Min. Order: 1KG
- Purity: Min98% HPLC
|
| | Lrrk2 Inhibitor Basic information |
| Product Name: | Lrrk2 Inhibitor | | Synonyms: | 5,11-Dihydro-2-[[2-methoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one;LRRK2-IN-1;LRRK2-TN-1;CS-642;LRRK2-IN-1; LRRK2 INHIBITOR;2-((2-Methoxy-4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenyl)-amino)-5,11-dimethyl-;6H-Pyrimido[4,5-b][1,4]benzodiazepin-6-one, 5,11-dihydro-2-[[2-methoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dimethyl-;LRRK2-IN-1 USP/EP/BP | | CAS: | 1234480-84-2 | | MF: | C31H38N8O3 | | MW: | 570.69 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1234480-84-2.mol |  |
| | Lrrk2 Inhibitor Chemical Properties |
| Boiling point | 787.8±70.0 °C(Predicted) | | density | 1.278 | | storage temp. | Store at -20°C | | solubility | ≥28.55 mg/mL in DMSO; insoluble in H2O; ≥57.2 mg/mL in EtOH | | form | solid | | pka | 8.14±0.42(Predicted) | | color | Light yellow to yellow | | InChIKey | IWMCPJZTADUIFX-UHFFFAOYSA-N | | SMILES | CN1CCN(CC1)C2CCN(CC2)C(=O)C3=CC(=C(C=C3)NC4=NC=C5C(=N4)N(C6=CC=CC=C6C(=O)N5C)C)OC |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | Lrrk2 Inhibitor Usage And Synthesis |
| Description | Leucine-rich repeat kinase 2 (LRRK2) is an enzyme that interacts with parkin, a ligase that is part of the ubiquitin-proteasome system that mediates the targeting of proteins for degradation. Loss of function of the parkin protein leads to dopaminergic cell death. The development of Parkinson''s disease has been strongly associated with mutations in the LRRK2 gene that lead to increased kinase activity. LRRK2-IN-1 is a potent inhibitor of LRRK2 that inhibits both wild-type and G2019S mutant LRRK2 (IC50s = 13 and 6 nM, respectively). It is selective for LRRK2 over a large panel of other kinases. LRRK2-IN-1 treatment causes dephosphorylation of LRRK2, leading to its dissociation from 14-3-3 proteins, ubiquitination, and degradation. Inhibitors of LRRK2, including LRRK2-IN-1, stimulate macroautophagy in H4 neuroglioma cells. | | Uses | LRRK2-IN-1 is a benzodiazepine based derivative and is known as a selective inhibitor of the Parkinson''s disease kinase LRRK2. | | Definition | ChEBI: LRRK2-IN-1 is a member of the class of pyrimidobenzodiazepines that is 5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one carrying at C-2 on the pyrimidine ring a 4-[(4-methylpiperazin-1-yl)piperidine-1-carbonyl]-2-methoxyanilino substituent. It is an inhibitor of the Parkinson's disease kinase LRRK2. It has a role as an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor and an antineoplastic agent. It is a N-acylpiperidine, a N-alkylpiperazine, an aromatic ether, a pyrimidobenzodiazepine, an aromatic amine, a secondary amino compound and a tertiary amino compound. | | in vivo | LRRK2-IN-1 (100 mg/kg, i.p.) induces dephosphorylation of LRRK2 in the kidney of the mice[2]. Peritumoral injection of LRRK2-IN-1 (100 mg/kg) results in a significant decrease in tumor volume and weight of AsPC-1 tumor xenografts[4]. | | storage | Store at -20°C | | References | [1] XIANMING DENG. Characterization of a selective inhibitor of the Parkinson”s disease kinase LRRK2[J]. Nature chemical biology, 2011, 7 4: 203-205. DOI: 10.1038/nchembio.538
[2] JING ZHAO. LRRK2 dephosphorylation increases its ubiquitination.[J]. Biochemical Journal, 2015, 469 1: 107-120. DOI: 10.1042/bj20141305
[3] CLAUDIA MANZONI . Inhibition of LRRK2 kinase activity stimulates macroautophagy[J]. Biochimica et biophysica acta. Molecular cell research, 2013, 1833 12: Pages 2900-2910. DOI: 10.1016/j.bbamcr.2013.07.020
[4] ALAVI M V. Tau phosphorylation and OPA1 proteolysis are unrelated events: Implications for Alzheimer’s Disease[J]. Biochimica et biophysica acta. Molecular cell research, 2021, 1868 12: Article 119116. DOI: 10.1016/j.bbamcr.2021.119116 |
| | Lrrk2 Inhibitor Preparation Products And Raw materials |
|